SAM
CBAY

Shell Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Shell Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-25,990
Closed -$118K – 1566
2021
Q1 		$118K Buy
+25,990
New +$140K ﹤0.01% 1257

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Shell Asset Management's CBAY Position: Q2 2021 in Review

Shell Asset Management sold out of Cymabay Therapeutics (CBAY) in Q2 2021, closing a stake of 25,990 shares — an estimated $118K sold.

Shell Asset Management first reported a position in CBAY in Q1 2021 and held it in 1 quarter. The position peaked at $118K in Q1 2021. 113 funds tracked by Wall St. Rank hold CBAY as of Q2 2021.

  • Shell Asset Management reported no remaining Cymabay Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Shell Asset Management sold 25,990 Cymabay Therapeutics shares in Q2 2021, an estimated $118K.
  • Shell Asset Management first reported a position in Cymabay Therapeutics in Q1 2021 and held it in 1 quarter.
  • Shell Asset Management's Cymabay Therapeutics position peaked at $118K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2021.

Based on Shell Asset Management's 13F filing for Q2 2021, filed 12 Aug 2021.